Jacobio’s IND Accepted for Phase I/II Trial of BET Inhibitor JAB-8263
Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of...
Tag : Investigational New Drug
XellSmart Gets FDA Clearance for 3 Phase I INDs in CNS Cell Therapies
XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has...
Virpax Announces Positive Probudur™ Dose Range Study Results
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system...
Avirmax Begins IND Studies for ABI-201 Gene Therapy for AMD
Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug (IND)-enabling studies of...